PwC's IPO Chief: Market Is Selective, Not Shut, With 2027 Rebound in View
Just under 90 U.S. IPOs year to date versus a normal 125-175, says PwC's Mike Bellin — a selective market where durable revenue, scale and reasonable leverage still get deals done.
By Amara Osei
4 min read

What's News
- Just under 90 U.S. traditional IPOs priced year to date, versus 125-175 in a normal good year, per PwC's Mike Bellin.
- IPO momentum 'halted significantly' after September and October on rates, inflation and geopolitical uncertainty.
- Investors demand durable revenue, visible profitability and reasonable leverage; aggressive valuations pushed issuers to pause.
- Biotech M&A by large pharma is the engine behind biotech's IPO resurgence.
- Hundreds of companies sit in the IPO pipeline ready for a potential strong start to 2027.
By Amara Osei
The U.S. has logged just under 90 traditional IPOs year to date, well short of the 125 to 175 that mark a good year, according to Mike Bellin, partner and U.S. IPO services leader at PricewaterhouseCoopers. He says the market is selective, not closed — and hundreds of companies are queued for 2027.
"A good IPO year in the U.S. is anywhere from 125 to 175 traditional IPOs, and year to date we've seen just south of 90 or so," Bellin told Crunchbase News. "Is the market in trouble? I would say no. It's very selective. It's not shut. Quality issuers with readiness, the right story, the right metrics can still get their deals done."
How healthy is the IPO market right now?
Breadth, not just volume, defines this cycle, Bellin said. Industrial products have returned to market, alongside tech, consumer, energy, utilities and some financial services. The first three quarters were "pretty strong and broad." Then momentum "halted significantly since September and October."
The macro backdrop drove the slowdown: rates, inflation and geopolitical concerns. Valuation was the other big factor. Some issuers asked for "fairly aggressive valuations," and buyers balked.
"I believe many issuers decided to hit pause and wait for another window to open," Bellin said.
What do public investors want?
Two things dominate the buy-side checklist. The first is durable revenue — a growing base backed by strong, diverse customers, with a significant backlog of demand for the issuer's products or services.
The second is leverage. For heavily indebted companies in a rising-rate environment, investors ask two questions, Bellin said: Can they take on new leverage that creates profitable value? Can they refinance existing debt at higher rates? Walking into the capital markets with a reasonable leverage ratio — or an equity story that explains the return on invested debt capital — "makes a significant difference."
Scale matters too. Large companies, by revenue or assets depending on sector, "can almost dictate the window that they're going to go out in and do well." Smaller and midmarket issuers, outside life sciences and biotech, have struggled.
Will AI enthusiasm survive public-market scrutiny?
Bellin's answer is nuanced: "I think investors aren't skeptical of AI; they're skeptical of spend without visibility — visibility to future earnings, visibility to that revenue durability."
The market is separating AI companies with visible demand from those with only a narrative, he said. Cash generation and profitability are the second test — GAAP income, EBITDA, free cash flows or levered free cash flows all count. If a company isn't profitable, investors want a date.
"We haven't seen a period like this of development, of growth, ever before," Bellin said. "It's exciting, but I do think the market will discern between those companies that are public-company worthy and those that are not."
Uneven post-IPO trading performance reinforces that selectivity. Some newly public companies won big; others traded below expectations after pricing too aggressively. Still, Bellin said companies are arriving "better prepared now than ever, given this volatility."
What is driving biotech's comeback?
M&A is the engine. Large pharmaceutical companies, losing patents on profitable drugs, are hunting for the next generation of development assets — and many biotechs were bought by big pharma before ever reaching public markets.
That competition creates what Bellin called "a nice horse trade between an IPO opportunity with a lot of upside and an M&A exit with more certainty day one." Biotech IPO assets have traded well, feeding a flywheel effect that has spread through biotech but not the rest of the market in recent months.
Why are SPACs back in conversation?
Volatility is reviving SPAC talks. A SPAC sets "valuation certainty on day one," so a company knows the potential cash coming its way — subject to redemptions. Serial SPAC issuers also help: they understand the product, what makes a good de-SPAC candidate, and whether a target can hit the milestones in the offering document. A large inventory of SPACs still hunts for targets.
What happens in 2027?
"Hundreds of companies are in the pipeline, and they're ready to go when the market is," Bellin said. Much of the remainder of 2026 and the start of 2027 hinges on market momentum. He points to buy-side demand, significant available capital, a healthy AI ecosystem, energy issuers, returning consumer and industrial products, and active private equity — which was very active in 2026 and should stay that way.
"I think we're in for a strong year, but it will remain selective," Bellin said.
Original: crunchbase.com
More from Amara Osei
Show full bio
Senior reporter covering companies, deals and strategy in entrepreneurship, startups and venture funding at Business Bearings.
2,157 articles